100 related articles for article (PubMed ID: 8184567)
1. [Serum thymidine kinase in multiple myeloma: II. Relation to disease activity and stage].
Scudla V; Papajík T; Bacovský J; Budíková M; Klímová D
Vnitr Lek; 1994 Mar; 40(3):157-62. PubMed ID: 8184567
[TBL] [Abstract][Full Text] [Related]
2. [Serum thymidine kinase in multiple myeloma: I. Relation to selected laboratory indicators in the disease].
Scudla V; Bacovský J; Papajík T; Budíková M; Srovnalík K
Vnitr Lek; 1994 Mar; 40(3):151-6. PubMed ID: 8184566
[TBL] [Abstract][Full Text] [Related]
3. [Relation of the soluble cytoadhesion molecules VCAM-1 and ICAM-1 to selected clinical and laboratory indicators in multiple myeloma].
Scudla V; Budíková M; Bacovský J; Ordeltová M; Opíchalová D; Heincová V
Vnitr Lek; 1999 Oct; 45(10):583-90. PubMed ID: 10951865
[TBL] [Abstract][Full Text] [Related]
4. [Serum interleukin-6 in multiple myeloma. II. Relation to activity and stage of disease].
Scudla V; Bacovský J; Budíková M; Srovnalík K; Kubalová D
Vnitr Lek; 1995 Sep; 41(9):599-604. PubMed ID: 7483350
[TBL] [Abstract][Full Text] [Related]
5. Serum thymidine kinase in non-Hodgkin lymphomas with special regard to multiple myeloma.
Poley S; Stieber P; Nüssler V; Pahl H; Fateh-Moghadam A
Anticancer Res; 1997; 17(4B):3025-9. PubMed ID: 9329592
[TBL] [Abstract][Full Text] [Related]
6. [Determination of the bromodeoxyuridine index in multiple myeloma. II. Relation to level of advancement and disease activity].
Scudla V; Ordeltová M; Bacovský J; Spidlová A; Vavrdová V; Sedlár D
Vnitr Lek; 1996 Aug; 42(8):545-50. PubMed ID: 8967024
[TBL] [Abstract][Full Text] [Related]
7. [Soluble interleukin-6 receptors in the serum in multiple myeloma].
Scudla V; Kubalová D; Bacovský J; Lukes J; Vavrdová V
Cas Lek Cesk; 1996 Nov; 135(22):719-22. PubMed ID: 8998823
[TBL] [Abstract][Full Text] [Related]
8. [Clinical importance of the paraprotein index in multiple myeloma].
Papajík T; Bacovský J; Zadrazil J; Budíková M; Faltýnek L; Scudla V
Vnitr Lek; 1994 Aug; 40(8):502-5. PubMed ID: 7941436
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of serum thymidine kinase and beta 2 microglobulin in subjects affected by multiple myeloma.
Musolino C; Allegra A; Orlando A; Grosso P; Alonci A; Cincotta M; Squadrito G
Riv Eur Sci Med Farmacol; 1990; 12(4-5):233-8. PubMed ID: 2103961
[TBL] [Abstract][Full Text] [Related]
10. [Importance of determining the propidium-iodide index of plasmacytes in multiple myeloma. II. Relation to disease extent and activity].
Scudla V; Ordeltová M; Spidlová A; Bacovský J; Budíková M; Srovnalík K
Vnitr Lek; 1999 Jun; 45(6):336-41. PubMed ID: 11045168
[TBL] [Abstract][Full Text] [Related]
11. International prognostic index (IPI)--a critical comparison with five multiple myeloma staging systems in the group of 270 patients treated by conventional chemotherapy.
Scudla V; Zemanova M; Minarik J; Bacovsky J; Ordeltova M; Indrak K; Budikova M; Dusek L; Farbiakova V
Neoplasma; 2006; 53(4):277-84. PubMed ID: 16830053
[TBL] [Abstract][Full Text] [Related]
12. [The bromodeoxyuridine index in multiple myeloma. I. Relation with selected laboratory indicators of the disease].
Scudla V; Ordeltová M; Bacovský J; Spidlová A; Budíková M; Kubalová D; Zivná J
Vnitr Lek; 1996 Jul; 42(7):458-62. PubMed ID: 8928421
[TBL] [Abstract][Full Text] [Related]
13. [Serum beta 2-microglobulin in multiple myeloma. I. Relation to selected indicators, clinical stage and disease prognosis].
Scudla V; Budíková M; Fischerová E; Raska I; Vavrdová V
Vnitr Lek; 1991 Apr; 37(4):342-51. PubMed ID: 2053304
[TBL] [Abstract][Full Text] [Related]
14. [Prognostic value of the new international staging system in multiple myeloma. Comparison with Durie-Salmon staging system].
Conté L G; Figueroa M G; Lois V V; Cabrera C ME; León R A; García L H; Rojas R H
Rev Med Chil; 2008 Jan; 136(1):7-12. PubMed ID: 18483648
[TBL] [Abstract][Full Text] [Related]
15. [The enzymatic character of myeloma cell].
Yoshikawa O; Furuya T; Toyama K
Nihon Rinsho; 1995 Mar; 53(3):598-602. PubMed ID: 7699891
[TBL] [Abstract][Full Text] [Related]
16. Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma.
Alexandrakis MG; Passam FH; Boula A; Christophoridou A; Aloizos G; Roussou P; Kyriakou DS
Ann Hematol; 2003 Jan; 82(1):19-23. PubMed ID: 12574959
[TBL] [Abstract][Full Text] [Related]
17. Serum level of interleukin-16 in multiple myeloma patients and its relationship to disease activity.
Alexandrakis MG; Passam FH; Kyriakou DS; Christophoridou AV; Perisinakis K; Hatzivasili A; Foudoulakis A; Castanas E
Am J Hematol; 2004 Feb; 75(2):101-6. PubMed ID: 14755377
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of serum neural cell adhesion molecule as a prognostic marker in multiple myeloma.
Poley S; Stieber P; Nüssler V; Pahl H; Fateh-Moghadam A
Anticancer Res; 1997; 17(4B):3021-4. PubMed ID: 9329591
[TBL] [Abstract][Full Text] [Related]
19. [Importance of determining the propidium-iodide index of plasmacytes in multiple myeloma. I. Relation to selected laboratory indicators of the disease].
Scudla V; Ordeltová M; Spidlová A; Bacovský J; Kurasová J; Vránová M
Vnitr Lek; 1999 Jun; 45(6):331-5. PubMed ID: 11045167
[TBL] [Abstract][Full Text] [Related]
20. Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: correlation with markers of disease activity.
Alexandrakis MG; Passam FH; Sfiridaki A; Kandidaki E; Roussou P; Kyriakou DS
Am J Hematol; 2003 Apr; 72(4):229-33. PubMed ID: 12666132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
